Edict Acquisition (Tables) (Edict Acquisition [Member])

3 Months Ended

Mar. 31, 2014

Edict Acquisition [Member]

Business Acquisition [Line Items]

Schedule of Business Combination, Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following items ($ amounts in thousands):

Cash paid for equity	$	20,659
Contingent purchase price liabilities	11,641		(1)
Cash paid for assumed indebtedness	4,300
Total consideration	$	36,600

(1) Contingent purchase price liabilities represent subsequent milestone payments related to successful FDA inspection of the Par Formulations manufacturing facility and ANDA filings.  All contingent purchase price liabilities were paid in full within 18 months of the acquisition date.